Venus Medtech (Hangzhou) Inc.

Equities

2500

CNE100003PJ8

Medical Equipment, Supplies & Distribution

Market Closed - Hong Kong S.E. 03:08:30 2023-11-22 am EST 5-day change 1st Jan Change
5.62 HKD -0.71% Intraday chart for Venus Medtech (Hangzhou) Inc. -.--% -.--%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% MT
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Venus Medtech Inc.(SEHK:2500) dropped from S&P Global BMI Index CI
Venus Medtech Inc. Announces That Wan Yee Joseph Lau, an Independent Non-Executive Director, the Chairman of the Nomination Committee and A Member of Each of the Remuneration and Assessment Committee and the Audit Committee of the Board, Passed Away CI
Venus Medtech Names Former 3SBio Finance Chief as CFO MT
Venus Medtech Inc. Appoints Fei Wang as the Chief Financial Officer CI
Venus Medtech Gets Trading Resumption Guidance MT
Venus Medtech Inc. Approves Mr. Liqiao Ma as an Executive Director CI
Venus Medtech Concludes Probe into Funds Loaned to Ex-Directors; Declares Remedial Action MT
Venus Medtech to Market Valgen Medtech's Heart Valve Repair System Across China MT
Venus Medtech Inc. Announces Executive Changes CI
Venus Medtech Names Joint CEO MT
Venus Medtech Inc. Announces Appointment of Mr. Lim Housen (Lin Haosheng) as Joint Chief Executive Officer with Effect from September 22, 2023 CI
Venus Medtech's H1 Attributable Loss Widens MT
Venus Medtech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
US FDA Grants Clinical Trial Approval to Venus Medtech's Pulmonary Valve Replacement MT
Venus Medtech Inc. Announces it's Self-Developed Transcatheter Pulmonary Valve Replacement System VenusP-Valve Received the Approval of IDE (Investigational Device Exemption) Application from the US Food and Drug Administration CI
Venus Medtech’s General Manager Boosts Shareholding to 12% MT
Venus Medtech Inc. Announces Resignation of Haiyue Ma as Joint Company Secretary CI
Venus Medtech Inc. Announces Resignation of Haiyue Ma as CFO CI
Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Venus Medtech Completes Patient Enrollment for Confirmatory Trial of Liwen RF Ablation System MT
Venus Medtech Inc. Announces Completion of Full Patient Enrollment for Confirmatory Clinical Trial of Liwen RF in China CI
Venus Medtech Inc. Announces Board Changes CI
Venus Medtech Inc. Announces Resignation of Lim Hou-Sen as an Executive Director and Nisa Bernice Wing-Yu Leung as Non-Executive Director and Vice Chairwoman CI
Chart Venus Medtech (Hangzhou) Inc.
More charts
Venus MedTech (HangZhou) Inc. is a China-based company engaged in the research, development, manufacture and sales of minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
5.157 CNY
Average target price
7.988 CNY
Spread / Average Target
+54.90%
Consensus
  1. Stock Market
  2. Equities
  3. 2500 Stock
  4. News Venus Medtech (Hangzhou) Inc.
  5. Venus Medtech Taking Full Ownership of Israeli Medical Device Maker Mitraltech; Shares Jump 3%